Brief: Neurosense Receives Positive FDA Feedback On Phase 3 Study Design For Primec

Neurosense Therapeutics

11/12/2024 14:29

Dec 11 (Reuters) - Neurosense Therapeutics  NRSN.O :
    * NEUROSENSE RECEIVES POSITIVE FDA FEEDBACK ON PHASE 3 STUDY
DESIGN FOR PRIMEC
    * NEUROSENSE THERAPEUTICS LTD: PLANS TO SUBMIT FINAL
PROTOCOL TO
FDA DURING FIRST HALF OF 2025

Source text:  ID:nPn1S7wTWa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))